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Abstract
Background: Chronic hepatitis C infection (CHC) is a major healthcare problem. Effective anti-
viral therapy is available. To maximise population effectiveness, co-ordinated services for detection
and management of patients with CHC are required. There is a need to determine patterns of
healthcare delivery to plan improvements. A study was conducted to determine workload,
configuration and care processes of current UK services available to manage patients with CHC.
Methods: A cross-sectional questionnaire survey of consultant members of British Association for
the Study of the Liver (n = 53), Infectious Disease consultants (n = 43), and a 1 in 5 sample of
Genito-Urinary Medicine (n = 48) and gastroenterologists (n = 200).
Results: Response rate was 70%. 40% of respondents provided a comprehensive service (included
treatment and follow-up): speciality of clinical leads identified as Hepatology (37%);
Gastroenterology (47%); and Infectious Disease (16%). The estimated number of patients managed
by respondents was about 23,000 with an upward trend over the previous 3 years. There was
variation between comprehensive service providers, including unit size, eligibility criteria for
treatment, and drug regimes. Key barriers to quality of care identified were staffing capacity, funding
of treatment and patient non-attendance. Most English strategic health authorities had at least one
comprehensive service provider.
Conclusion: There was significant variation in all aspects of the patient pathway which may
contribute to inequity of health care provision. Services need to be expanded to form geographical
clinical networks, and properly resourced to ensure greater uptake and more equitable delivery of
services if the future burden of chronic liver disease is to be reduced.
Background
Chronic Hepatitis C (CHC) is a major cause of serious
liver disease[1,2]. Effective viral eradication therapy using
combinations of anti-viral agents is available [3,4] and
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Since the screening of blood donors for hepatitis C (HCV)
was introduced, the main risk groups are ex and current
injecting drug-users (IDUs), who are hard to reach by
health care services.
National Strategies for Hepatitis C in the UK have been
published [7-9]. These recognize the need for a systematic
approach to the identification, testing, referral, selection
for treatment and follow-up of HCV positive patients.
They recommend the establishment of managed clinical
networks for CHC -managed clinical networks may be
defined as linked groups of health professionals working
in a coordinated manner across organisations and struc-
tural boundaries, with a common strategic agenda to pro-
mote health improvement and reduce health inequalities
for a given population thus maximising shared resources
in a coordinated way[10]. They also suggested a national
survey of current practice and service configuration to
establish baseline information upon which to plan the
future services for patients with CHC. This study reports
on the findings of such a survey.
Methods
The four clinical specialties most likely to manage patients
with Hepatitis C – Gastroenterology (GI), Genito-Urinary
Medicine (GUM), Hepatology, and Infectious Diseases
(ID) were targeted by postal questionnaire sent out in
2002. The sample was drawn from memberships lists sup-
plied by the respective professional organisations.
All consultant/equivalent grade members of the British
Association for the Study of the Liver (BASL) were deemed
to be "hepatologists" by virtue of expressing a particular
interest in liver medicine.
A list of Infectious Disease Units in the UK was provided
and a consultant Infectious Disease (ID) Physician from
each hospital was invited to participate.
Gastroenterologists at consultant grade were identified by
membership of British Society of Gastroenterology and a
1:5 random sample was taken, stratified by Health
Region. A similar approach was used to sample Genito-
Urinary Medicine consultants identified by membership
of the Association of Genito-Urinary Physicians.
An expert steering group was consulted in the design of a
self-completed questionnaire. This was piloted on 20 phy-
sicians randomly sampled from each of the four clinical
specialties, the comments from the pilot informing the
final questionnaire that was sent out to the whole sample
described above (see Additional file 1). Subjects who did
not have any role in the management of HCV infection
were asked to provide the name of the lead clinician who
fulfilled this role for their catchment area, and a question-
naire was then sent on to these individuals. Those who
did not respond were contacted once by telephone in
order to improve the response rate.
Respondents were asked to classify their service according
to the three following descriptors: "providing diagnostic
and investigative services but not treatment (diagnostic
investigative provider – DIP)"; "providing diagnostic test-
ing, investigations, treatment and follow-up of patients
(comprehensive service provider-CSP)"; and "no role in
the management of hepatitis C infection". Several ques-
tions asked for a response in terms of the percentage of
patients; these used groupings 0–4%, 5–9%, 10–24%,
25–49%, 50–74%, 75+%.
The information derived from returned questionnaires
was analysed using SPSS statistical package (SPSS for Win-




The response rate for the initial survey was 71% (203/
287). A further 57 clinicians were identified as providers
of a comprehensive service by respondents who did not
Table 1: Response rates & role in the care of patients with Chronic Hepatitis C by specialty
Management role by specialty*




No role n (%) DIP n (%) CSP n (%)
GI 200 (58) 124 (52) 28 (64) 50 (51) 46 (47)
Hepatology 53 (15) 48 (19) 3 (7) 9 (9) 36 (37)
ID 43 (13) 30 (13) 1 (2) 14 (14) 15 (16)
GUM 48 (14) 38 (16) 12 (27) 26 (26) 0 (0)
Total 344 (100) 240 (70) 44 (100) 99 (100) 97 (100)
DIP = diagnostic & investigative provide CSP = comprehensive service provider
* e.g. number (%) of management role provided by specialityPage 2 of 9
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responded giving a total response rate of 70% (240/344).
40% (97) of respondents were comprehensive service pro-
viders (CSPs). 46 (47%) of the CSPs had a gastroenterol-
ogy lead, 36 (37%) a hepatology lead, and 15 (16%) an
ID lead. GUM physicians provided a service up to DIP 26
(26%), but none were CSPs.
Almost three-quarters of hepatologists and half of ID phy-
sicians were CSPs. The majority of gastroenterologists
(63%) provided either no role or a DIP service for patients
with HCV (see Table 1).
DIPs were mostly sited in small or medium sized district
hospitals with an urban/mixed urban catchment popula-
tion. Most looked after a small number of patients with
HCV infection, with 52% diagnosing less than 10 patients
with HCV (2001) and 82% diagnosing less than 20
patients.
More of the CSPs covered catchment populations of over
1 million (15%) compared to DIP (8%), with more of the
largest catchment areas being served by hepatologists (p =
0.006). CSPs saw a larger new caseload with 50% of
respondents seeing >40 patients a year.
The total estimated prevalent population of patients with
CHC managed by the responding CSPs was 22,100, of
which 50% were managed by hepatologists, and 25%
each by ID physicians and gastroenterologists. The
number of prevalent patients varied between CSPs, the
median number was in the range 100–500 patients; at the
extremes nine CSPs managed under 20 cases in total and
three CSPs were managing over 1000 patients in total.
(There may be some uncertainty in who is included in
these figures, as the questionnaire asked for patient num-
bers "currently under your care" which may include those
defaulting and not yet discharged back to Primary Care).
One third of CSPs saw >75 new cases of HCV in 2001.
Identification and referral of HCV patients (Table 2)
For half of the CSPs the diagnosis of HCV infection was
already made at the time of referral. Of patients referred
with an established diagnosis, 41% originated in primary
care, 24% in drug and alcohol services, 14% in prison
healthcare and 14% from GUM physicians.
Of those referrals where the CSP unit established the diag-
nosis of Hepatitis C, most came from primary care (73%),
other clinical specialties (mainly gastroenterology (17%)
and ID (12%)), and drug and alcohol agencies (14%).
50% (48) of CSPs were aware of active case finding in
their catchment populations, with 19% (9) of case finding
being performed in accordance with a written policy.
Most case finding was performed in patients with abnor-
mal liver tests, or with identified risk factors such as IDU.
24% (22) of CSPs had outreach services, most commonly
in prisons (17) or drug and Alcohol services (9).
Table 2: Referral pathways of HCV patients to comprehensive service providers
Source of referral for patients with established HCV diagnosis to the CSP % of CSPs*








Source of referral when HCV diagnosed by the CSP % of CSPs








*Totals can exceed 100% as more than one responsePage 3 of 9
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ment were high, with the median per CSP being 10–24%.
There was no association between the default rate and size
of unit (p = 0.19).
Patient management
Co-ordinated management strategies for patients with
HCV were reported by 45%% (44) of CSPs, with formal
collaboration between CSP and other services. The most
common formal links were between the CSP and Drug
and Alcohol Teams (n = 37), GUM services (n = 30), pris-
ons (n = 22), primary care (n = 20) and homeless units (n
= 14). Other links included asylum seekers (2), other
medical specialities (5) and a renal dialysis unit (1).
57% of CSPs had a hospital based multidisciplinary team
(MDT) that met regularly to discuss the management of
HCV patients. The composition varied but most com-
monly included the consultant from the lead clinical spe-
cialty, specialist nurse, pathologist, radiologist and DAT
representative. Only three MDTs had a patient representa-
tive.
The larger units led by Hepatologists and ID Physicians
had more access to specialist nurses, who played a key role
in starting treatment and in monitoring patients.
Drug treatment
10–24% (median) of new patients was considered eligible
for anti-viral drug treatment. Table 3 shows the factors
used to determine eligibility. Over 90% of responding
CSPs used severity of hepatitis, more than 60% of
respondents used age, and 90% used co-morbidity. The
most important single reason reported for ineligibility, by
over 60% of CSPs, was ongoing illicit drug use. The most
common reason given for why patients refused treatment
was concern over side effects (see Table 3).
24% of CSPs reported that over 90% of the eligible
patients were treated, with 50% reporting that over 75%
of eligible patients were treated (median range 50%–
74%). The majority were not treated in clinical trials.
35% of CSPs offered treatment to patients with mild hep-
atitis -of these 95% offered treatment to patients with
symptoms and 49% to patients who were asymptomatic.
Virtually all of the respondents definitely offered treat-
ment to patients with moderate or severe hepatitis /cirrho-
sis (Child-Pugh A), 48% (38) (with 9% (7) "maybe treat")
also treated those with Child-Pugh B, and 14% (11)
treated patients with Child Pugh C cirrhosis. 16% (and
8% "maybe") offered antiviral treatment for those await-
ing transplantation. In the majority of cases there was no
link between the CSP treating HCV related end-stage liver
disease with anti-virals and whether they were transplant
centres or had close collaboration with transplant centres.
(Child Pugh is a clinical score to evaluate prognosis in cir-
rhosis using bilirubin, albumin, INR, ascites and enceph-
alopathy which are awarded points depending on values.,
Table 3: Eligibility for anti-viral treatment of patients with Hepatitis C and reasons for patient refusal
Question Choices Percentage of units saying yes
Which of the following criteria do you consider in 




Severity of hepatitis 93
Co-morbidities 95
73% current/future drug/alcohol use
What were the main reasons for patients' 
ineligibility?
Ongoing drug use 62
Ongoing alcohol use 21
Psychiatric disorder 11
Other medical co-morbidities 3
Cardiovascular disease 2
What are main reasons for patient refusal of 
treatment?
Concern over side effects 49
Inconvenient to start treatment -work pressures 37
Refusal to modify chaotic lifestyle 30
Lack of belief of efficacy 15Page 4 of 9
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severity of disease Class A (5–6 points) Class B (7–9
points) Class C (10–15 points). Class A has a better prog-
nosis than B, which in turn has a better prognosis than
class C).
Two thirds (66%) of respondents currently used inter-
feron and ribavirin combination therapy and a majority
(59%) were using pegylated interferons. Those CSPs who
used pegylated interferon and ribavirin used it in 50–74%
of treated patients (median), and those CSPs who used
interferon and ribavirin used this regime in 25–49% of
treated patients (median) (see Table 4). Interferon and
pegylated interferon alone were used in the minority of
patients treated by CSPs (0–5%), Just over half (52%) of
CSPs reported that they used printed guidelines for dose
reduction and stopping therapy and 35% performed post
treatment liver biopsy.
The median rate of adherence to treatment reported was
75–90%, with the main reasons for stopping treatment
being 'patient initiated' and 'side effects'. There were no
significant differences in the percentage of CSPs reporting
higher levels of adherence by clinical specialty, presence
of a specialist nurse, or size of unit though the study is
underpowered to detect any differences.
For those patients not receiving treatment there was varia-
tion in practice for the follow-up of patients with different
degrees of severity of hepatitis. The median follow-up for
patients not on treatment with mild hepatitis was annu-
ally (66%), for moderate hepatitis it was every 6 months
(55%), and for severe hepatitis and cirrhosis it was every
3 months (47%).
The majority of CSPs (62%) had a database to record
information about patients with HCV and another 12%
were in the process of establishing a database. This varied
by clinical speciality from 57% for GI led units, 88% for
hepatologist and 93% for ID. 15 data systems were in
paper format and 57 were electronic (some units main-
tained both forms). There was concordance of minimum
data items collected.
Barriers to providing a high quality service for patients 
with Hepatitis C
82% of CSPs reported barriers in the management of
patients with Hepatitis C. The main factors are shown in
Table 5. Funding, staff capacity and patient non-attend-
ance were the most common. Biopsy waiting times
showed some differences between specialities, with 17
hepatologists and 4 ID physicians agreeing/strongly
agreeing that biopsy times are a barrier to care, and 6
Hepatologists and 9 ID physicians disagreeing.
Geographical distribution of services
In England, 27 out of 28 Strategic Health Authorities
(SHAs) had a CSP within their boundary (Figure 1). The
size of the CSP and the clinical discipline of the lead var-
ied, with some SHAs having a few smaller centres, and
others a single large provider. ID led units were concen-
trated in the North/Midlands of England and Scotland.
Table 4: Pattern of drug prescribing by CSP (2001)




% of patients receiving a 
particular drug regime as a % of 
overall prescribing by CSP* 
(Median)
0–5 25–49 50–74 0–5
Number of CSPs using drug 
regime
20 64 57 24
Table 5: Barriers to providing a high quality service
Reason Agree/strongly agree% Unsure % Disagree /strongly disagree %
Clinic waiting times 58 3 39
Biopsy waiting time 45 3 52
Staffing Capacity 76 12 16
Staffing Skill mix 42 15 43
Funding for Treatment 72 4 24
Patient Refusal 32 19 49
Patient non- attendance 80 3 17
Patient Identification 31 31 29Page 5 of 9
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led by a hepatologist and one quarter did not have a hepa-
tologist within the SHA. Over half of the SHAs had ≥ 5
prisons, and there was no obvious relationship between
the presence of CSPs and the number of prisons.
In Scotland, there were CSPs in 6 out of 15 health boards,
with the larger centres being in Glasgow, Edinburgh and
Dundee, and they were mostly led by ID physicians or gas-
troenterologists. In Wales five CSPs were identified, one of
which was led by an ID physician and four by gastroenter-
ologists.
Discussion
This survey included a national representative sample of
consultant clinicians managing patients with Hepatitis C.
Distribution of comprehensive service providers in the UK by health geography (SHA, Health Board), numbers of prevalent patients with chr nic hepatitis C managed per provider, and clinical lead specialityFigure 1
Distribution of comprehensive service providers in the UK by health geography (SHA, Health Board), numbers of prevalent 
patients with chronic hepatitis C managed per provider, and clinical lead speciality.Page 6 of 9
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of respondents. By conducting a two stage process we
think we captured most CSPs. The study revealed varia-
tions in structure and process at all stages of the patient
pathway, such as size of unit, clinical lead, eligibility crite-
ria for treatment, and drug regimes used. Barriers to care
were identified which contributed to difficulties experi-
enced by services in coping with the present burden of
patients in the hospital system. Such variation in health-
care provision may contribute to inequity of care for peo-
ple with Hepatitis C. Having provided an analysis of the
provision of Hepatitis C services in the UK, this survey can
be used as a base for future planning and development,
and the urgent need to address inequalities.
This survey found that the majority of patients within
CSPs are not receiving anti-viral treatment. This is sup-
ported by industry figures of approximately 10,000 UK
patients treated so far (personal communication Schering
Plough, Roche)[11]. This contrasts with practice in
Europe. 56% of positive subjects in France now know
their serological status and 75,000 have been treated.
100,000 have been diagnosed in Germany, with 20–
30,000 treated. Italy has treated approximately 100,000
patients, one third of diagnoses. In France through a wider
screening policy (including prisoners, antenatal clinics,
and social security medicals), reimbursement of private
laboratories, and greater awareness, testing increased by
26% and 1.2 million tests were performed in France
between 2000 and 2002. Testing is freely available anon-
ymously in French universities, town centres and hospital
family planning clinics in addition to prisons and drugs
clinics. Germany has a similar screening strategy (personal
communication Bethan Bennett Lloyd). There is no for-
mal screening programme in the UK except for blood
donors, although the Hepatitis C Action Plan plans a case
finding strategy for named high risk groups.
NICE guidance in the UK recommends that interferon
(pegylated and non pegylated) and ribavirin be used in
moderate and severe CHC. A.European consensus (1999)
statement recommended that moderate/severe necroin-
flammation and/or fibrosis be treated, and in the USA
treatment of moderate and severe disease with pegylated
interferon and ribavirin is recommended [12-14]. Despite
the national guidance many CSPs found that funding for
treatment was a barrier to care, leading to a persistence of
postcode prescribing with regional variation in access to
treatment. The survey showed that there was a high attri-
tion rate of people who could potentially benefit from
specialist services, at the point of identification of high
risk groups, diagnosis, referral to specialist services,
defaulting from clinic, determination of eligibility for
treatment and those finally receiving treatment. Further
elaboration on the reasons for this attrition may contrib-
ute to more effective strategies aimed at increasing the
number of people potentially eligible for treatment being
seen by specialist services.
The true prevalence of CHC in the UK is unknown. Esti-
mates remain vulnerable to the lack of information of the
"ever" and current IDU population at risk of CHC, leading
to wide ranges around best guesses. The cumulative
number of antibody positive HCV tests reported in the UK
is 59,000 (1992–2003)[15,16], which suggests that even
all those who have a antibody positive test are not being
managed by specialist services. Most people with CHC are
therefore likely to be unknown to secondary care, and of
these there are those who are undetected and unknown to
services, those in contact with services but not tested,
those who are diagnosed but who are not referred to spe-
cialist health services, and those who are referred but do
not attend (see figure 2). Best estimates derived by prag-
matic modelling of this prevalent population range from
200,000–500,000 [17,18] (unpublished data- submitted
for publication Parkes J. et al). By 2020, using existing
models, the future burden of cirrhosis due to HCV is esti-
mated to be three times that at present, posing major
resource implications for services [19-22].
How can services identified by this study be improved to
meet the needs of patients with CHC, and reduce the
future burden of liver disease? This survey found that a
large number of gastroenterologists were caring for a
small number of patients with CHC. However, most
patients with CHC were cared for by medium sized units
led by hepatologists or ID physicians. The diversity in clin-
The disease iceberg for Hepatitis CFigure 2
The disease iceberg for Hepatitis C.Page 7 of 9
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relative lack of co-ordination in care and the low aware-
ness of Hepatitis C in the UK. Recent national initiatives
may have gone some way to improve this situation and
should be built on to provide a cohesive national service
for people with CHC. Models of best practice were identi-
fied by this survey (data not presented), the salient feature
being coordination and cooperation between the relevant
specialities and settings in a locality involved in managing
people with CHC.[23] The variation in management strat-
egies including treatment despite national standards of
care may also be well served by increased cohesion of serv-
ices locally and nationally, with the aim to have a consist-
ent high quality evidence based service delivered to
patients with CHC no matter where they live.
Staff capacity was identified as a major barrier to care,
with all aspects of a CHC service needing additional
resources. As the number of patients with advanced liver
disease due to CHC grows, this will become ever more
pressing with major implications for health care commis-
sioners and providers with respect to recruitment, training
and funding of specialised hepatology staff.
Although there has been no co-ordinated policy driving
service configuration, there was a CSP in virtually all Eng-
lish SHAs, and in many Welsh and Scottish health dis-
tricts. These centres provide the potential for building
managed clinical networks based on populations of
around 1–2 million as recommended by national poli-
cies. Such networks could act to ensure national standards
and equity of access to services, working together across
localities and coordinating services across the country.
CSPs should be developed within each network with a
critical mass of staff, clear referral guidelines, outreach
arrangements, and a unified information system to sup-
port these networks and to monitor service performance.
The early establishment of a comprehensive computerised
IM&T strategy is needed as a matter of some urgency. It is
encouraging that many of the CSPs were collecting
homogenous data on CHC patients, however there was
variation in the computer systems used and many units
were unable to put data on to electronic systems due to
lack of staff.
Commissioners of HCV services will need to assess the
population need in their area, which will be driven pre-
dominantly by local IDU prevalence (current and ex),
including that within the local prison population [24,25].
Targeting of high risk groups such as IDUs in prisons has
been shown to be not systematised, with this survey
reporting only 17 CSPs who had collaborative links or
outreach clinics in prisons out of a total of 158 UK prisons
[26-29]. More effort is needed to access this hard to reach
population whilst they are detained, with risk minimisa-
tion, case finding and treatment of eligible people. More
research is needed to evaluate models of delivery of Hep-
atitis C services to prisoners, both in prison and after their
discharge.
Limitations to this survey include inaccuracies in the pro-
fessional lists used to sample participants. Whilst this may
have led us to miss specialist centres, coverage appears to
be good. Hepatology is not yet recognised as a specialty,
and we had to assume that those clinicians belonging to
national specialist groups have an interest in liver disease
and we used this as a definition of hepatologist. The quan-
titative responses were self -reported and may not have
been derived from accurately recorded sources. Using the
DIP and CSP classification was imperfect as several DIPs
reported fluidity between categories depending on exter-
nal factors such as resources.
Conclusion
This survey has examined how individuals are identified,
diagnosed and treated. It has shown that there is inequity
and variation in the management of people with CHC in
the UK, with staffing and funding of treatment as key bar-
riers to care. However, based on existing specialist centres
identified by this survey, there are opportunities to pro-
vide planned care via managed clinical networks sup-
ported by a national information strategy. Urgent
investment is needed to improve the identification, refer-
ral and management of people with CHC, and to maxi-
mize the opportunities to reduce the sequelae of serious
liver disease.
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